RGD Reference Report - Serum Mullerian Inhibiting Substance/anti-Mullerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Serum Mullerian Inhibiting Substance/anti-Mullerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology.

Authors: Chang, HL  Pahlavan, N  Halpern, EF  MacLaughlin, DT 
Citation: Chang HL, etal., Gynecol Oncol. 2009 Jul;114(1):57-60. Epub 2009 Apr 8.
RGD ID: 2315639
Pubmed: PMID:19359032   (View Abstract at PubMed)
PMCID: PMC2756071   (View Article at PubMed Central)
DOI: DOI:10.1016/j.ygyno.2009.02.023   (Journal Full-text)

OBJECTIVES: Granulosa cell tumors (GCTs) comprise 2-5% of ovarian tumors. Serum Mullerian Inhibiting Substance (MIS, also known as anti-Mullerian hormone, or AMH) levels have been validated as a marker of GCT recurrence and progression. There has been little correlation between serum MIS/AMH levels and several clinical parameters in GCTs, including tumor burden. We have performed a retrospective review correlating aggregate tumor mass as reported by pathologic examination or by radiology with serum MIS/AMH levels drawn on the date of examination. METHODS: We retrospectively identified 32 GCT patients at our institution over the last 15 years who had serum MIS/AMH measurements. Patients who had serum MIS/AMH measurements within three days of surgery or on the same day as abdominal computerized tomography scan (CT) or magnetic resonance imaging (MRI) were further evaluated. RESULTS: We found a significant direct correlation between patient serum MIS/AMH levels and gross aggregate tumor mass determined by pathology (slope=15.4+/-6.06, r=0.65, p<0.04) or by radiographic aggregate tumor mass for all data points identified (slope=0.07+/-0.03, r=0.33, p<0.04) and after correcting for selection bias (slope=1.45+/-0.17, r=0.93, p<0.01). We also identified a significant difference between serum MIS/AMH levels between samples drawn the same day as negative and positive abdominal CT or MRI scans (8.16+/-1.54 vs. 158.7+/-32.2 ng/ml, p<0.0001). CONCLUSIONS: These data indicate a significant direct correlation between serum MIS/AMH levels and both gross and radiographic aggregate tumor mass in GCT patients. Together with the current literature, the present data argue for a more prominent role for serum MIS/AMH in the management of GCTs.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
granulosa cell tumor disease_progressionIEP 2315639 RGD 
granulosa cell tumor disease_progressionISOAMH (Homo sapiens)2315639; 2315639 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Amh  (anti-Mullerian hormone)

Genes (Mus musculus)
Amh  (anti-Mullerian hormone)

Genes (Homo sapiens)
AMH  (anti-Mullerian hormone)


Additional Information